Home4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Nakaraang pagsara
¥2,244.00
Sakop ng araw
¥2,247.00 - ¥2,274.00
Sakop ng taon
¥1,921.00 - ¥2,411.00
Market cap
119.94B JPY
Average na Volume
63.62K
P/E ratio
11.86
Dividend yield
1.99%
Primary exchange
TYO
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(JPY) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 20.97B | 14.11% |
Gastos sa pagpapatakbo | 12.52B | 14.20% |
Net na kita | 1.85B | -25.47% |
Net profit margin | 8.82 | -34.67% |
Kita sa bawat share | — | — |
EBITDA | 4.39B | 8.29% |
Aktuwal na % ng binabayarang buwis | 17.59% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(JPY) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 24.36B | 31.90% |
Kabuuang asset | 158.34B | 6.87% |
Kabuuang sagutin | 69.77B | -3.36% |
Kabuuang equity | 88.57B | — |
Natitirang share | 44.08M | — |
Presyo para makapag-book | 1.12 | — |
Return on assets | 4.06% | — |
Return on capital | 4.89% | — |
Cash Flow
Net change in cash
(JPY) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | 1.85B | -25.47% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Itinatag
Dis 22, 1955
Website
Mga Empleyado
1,777